Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) EBIT Margin (2016 - 2021)

Historic EBIT Margin for Neurocrine Biosciences (NBIX) over the last 11 years, with Q3 2021 value amounting to 15.03%.

  • Neurocrine Biosciences' EBIT Margin rose 321700.0% to 15.03% in Q3 2021 from the same period last year, while for Sep 2021 it was 8.84%, marking a year-over-year decrease of 46000.0%. This contributed to the annual value of 9.17% for FY2019, which is 9900.0% up from last year.
  • Per Neurocrine Biosciences' latest filing, its EBIT Margin stood at 15.03% for Q3 2021, which was up 321700.0% from 21.74% recorded in Q2 2021.
  • In the past 5 years, Neurocrine Biosciences' EBIT Margin registered a high of 40.57% during Q3 2019, and its lowest value of 903.99% during Q2 2017.
  • Over the past 5 years, Neurocrine Biosciences' median EBIT Margin value was 15.03% (recorded in 2021), while the average stood at 47.89%.
  • Its EBIT Margin has fluctuated over the past 5 years, first skyrocketed by 9020800bps in 2018, then plummeted by -577000bps in 2020.
  • Neurocrine Biosciences' EBIT Margin (Quarter) stood at 12.52% in 2017, then surged by 33bps to 16.63% in 2018, then grew by 20bps to 19.98% in 2019, then crashed by -186bps to 17.14% in 2020, then surged by 188bps to 15.03% in 2021.
  • Its EBIT Margin was 15.03% in Q3 2021, compared to 21.74% in Q2 2021 and 13.31% in Q1 2021.